If the scale says you lost 40 pounds, that is only part of the story.
The next question is: what did you lose?
Weight-loss medications have changed
obesity treatment dramatically. GLP-1 and GLP-1/GIP medications can
produce an amount of weight loss that was difficult to achieve with
lifestyle treatment alone for many people.
That is a very good thing.
But rapid weight loss creates a problem that deserves more attention:
your body does not remove only fat.
Weight and fat are not synonyms.
Body weight includes fat, muscle, organs, bone, water and everything
else that happens to be inside you when you step on a scale.
During meaningful weight loss, some lean mass is usually lost along with
fat mass.
Studies of GLP-1-based therapies show that the majority of weight lost
is generally fat, but reductions in lean mass can occur as well.
The goal is less excess fat while maintaining as much strength,
muscle and physical capacity as reasonably possible.
Why should we care about muscle?
Muscle is not decorative.
It helps us stand up, climb stairs, stabilize joints, maintain
independence, regulate glucose and recover from illness.
This becomes even more important as we age because adults already tend
to lose muscle mass and strength over time.
in celebrating.
So what do we do differently?
First, we stop treating nutrition during weight loss as:
eat as little as possible because the medication makes that easy.
Adequate protein matters. Enough overall nutrition matters.
Second, we give muscle a reason to stay.
Walking is excellent for health, but resistance exercise provides a
different physiologic signal—one specifically asking muscle to produce
force.
I care about the 70-year-old version of you too.
A successful weight-loss plan should make that future person lighter
when appropriate, but also strong enough to live their life.
The number on the scale is useful.
It is not the entire outcome.
Changes in Lean Body Mass With GLP-1-Based Therapies
Review of body-composition findings during GLP-1 treatment.
Semaglutide and Lean Mass — Systematic Review, 2024
Review of fat- and lean-mass changes during semaglutide-associated
weight loss.
